002773 Chengdu Kanghong Pharmaceutical Group
- 22.29
- -0.03-0.13%
Chengdu Kanghong Pharmaceutical Group News
The Recent CN¥800m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773)
Key Insights Chengdu Kanghong Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion 54% of the business is held by the top 2 shareholders Using da
Kanghong Pharmaceutical (002773.SZ) plans to pay 3.8 yuan for every 10 shares in 2023, excluding interest on May 28
Kanghong Pharmaceutical (002773.SZ) announced that in 2023, the company plans to distribute cash red to all shareholders for every 10 shares...
Kanghong Pharmaceutical (002773.SZ): As of May 20, 2024, the number of shareholders of the company was 35,384
Gelonghui, May 21丨Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that as of May 20, 2024, the number of shareholders of the company was 35,384.
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Held Back By Insufficient Growth Even After Shares Climb 25%
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) shares have continued their recent momentum with a 25% gain in the last month alone. Taking a wider view, although not as strong as the
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug
Chengdu Kanghong Pharmaceutical Group's (SHE:002773) unit, Chengdu Hongji Biotechnology, will conduct clinical trials on the KH658 ophthalmic injection after receiving approval from China's National M
Kanghong Pharmaceutical (002773.SZ): Clinical trial of KH658 ophthalmic injection approved
According to Zhitong Finance App, Kanghong Pharmaceutical (002773.SZ) issued an announcement. On April 28, 2024, the KH658 ophthalmic injection declared by the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. obtained an approval notice for drug clinical trials from the China Drug Administration and agreed to carry out phase I/II clinical trials. According to reports, KH658 ophthalmic injection is the second product of Hongji Biotech to be approved for clinical trials in China and the US at the same time. It uses a novel adeno-associated virus with independent intellectual property rights and a cell-specific receptor design as a delivery carrier. It is easy to administer, is safe, and has cell-mediated efficacy
Kanghong Pharmaceutical (002773.SZ) announced 2023 annual results, net profit of 1,045 billion yuan, up 16.52% year-on-year
Kanghong Pharmaceutical (002773.SZ) disclosed its 2023 annual report. The company achieved operating income of 39 during the reporting period...
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid
Chengdu Kanghong Pharmaceutical Group's (SHE:002773) mosapride citrate tablets were selected for a centralized procurement bid of an alliance of 13 Chinese provinces, according to the company's disclo
Should Weakness in Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
With its stock down 4.4% over the past three months, it is easy to disregard Chengdu Kanghong Pharmaceutical Group (SZSE:002773). However, the company's fundamentals look pretty decent, and long-ter
Kanghong Pharmaceutical (002773.SZ): AI medical related business has not yet been developed
Gelonghui, March 20 | Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that the company is closely following the development trend of AI in the medical industry and is not currently developing AI medical related business.
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Shares Fly 25% But Investors Aren't Buying For Growth
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) shareholders are no doubt pleased to see that the share price has bounced 25% in the last month, although it is still struggling to make up
Kanghong Pharmaceutical (002773.SZ): As of February 29, 2024, the number of shareholders of the company was 38,934
Gelonghui March 1 | Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was 38,934.
Kanghong Pharmaceutical (002773.SZ): Subsidiary biosimilar KH917 injection clinical trial application approved
Gelonghui, Feb. 27丨Kanghong Pharmaceutical (002773.SZ) announced that recently, the KH917 injection clinical trial application declared by Beijing Kanghong Biomedical Co., Ltd. (hereinafter referred to as “Beijing Kanghong Biology”), a wholly-owned subsidiary of the company, obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to conduct clinical trials. According to reports, KH917 injection is a biosimilar drug developed by Beijing Kanghong Biology. This product can specifically bind to the cytokine interleukin 17A (IL-17A) and inhibit the latter's interaction with IL-17 receptors, affecting pro-inflammatory cytokines
Recent 11% Pullback Would Hurt Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Insiders
Key Insights Chengdu Kanghong Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 54% of the company Using data from
Kanghong Pharmaceutical (002773.SZ): The company has no studies related to fever
Gelonghui, January 30 | Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that the company is guided by clinical needs and continues to increase investment, in-depth research, and professional innovation in the fields of ophthalmology, neurology, oncology, etc. Up to now, the company has no studies related to fever.
Kanghong Pharmaceutical (002773.SZ): As of January 10, 2024, the number of shareholders of the company was 39,579
Gelonghui January 19 | Kanghong Pharmaceutical (002773.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 39,579.
There's No Escaping Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Muted Earnings
With a price-to-earnings (or "P/E") ratio of 17.7x Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) may be sending bullish signals at the moment, given that almost half of all companies in
Kanghong Pharmaceutical (002773.SZ)'s two products were included in the national medical insurance catalogue
Kanghong Pharmaceutical (002773.SZ) issued an announcement. On December 13, 2023, the website of the National Medical Security Administration...
Kanghong Pharmaceutical (002773.SZ): Compassip ophthalmic injections and escitalopram oxalate oral solution are included in the national medical insurance catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui December 13丨Kanghong Pharmaceutical (002773.SZ) announced that on December 13, 2023, the National Medical Security Administration website published the “Notice of the Ministry of Human Resources and Social Security of the National Health Insurance Administration on Issuance” (Health Insurance Development [2023] No. 30), Compazip Eye Injection (product name “Langmu”), and escitalopram oxalate oral solution (product name: “Bo Mingxin”, specification: C2HFNO meter: 120ml:120mg/ bottle) was included in “National Basics
Kanghong Pharmaceutical (002773.SZ): Escitalopram oxalate tablets approved for marketing
Gelonghui, December 8, Kanghong Pharmaceutical (002773.SZ) announced that the company recently received the “Drug Registration Certificate” (certificate number: 2023S01932, 2023S01933) for escitalopram oxalate tablets issued by the State Drug Administration for approval of registration. The original imported product of escitalopram oxalate tablets (specification: 5 mg, 10 mg) was approved for marketing in China in August 2005. The marketing license holder is H.Lundbecka/s. The indications are for the treatment of depression and the treatment of panic disorder with or without agoraphobia.
Analysis
Price Target
No Data
